Granted Patent B2

US 12,606,870 · App. 17/232,961 · Granted Apr 21, 2026

Inventors: Malek Faham (Pacifica, CA); Thomas Willis (San Francisco, CA)

Assignee: Adaptive Biotechnologies Corporation

C12Q1/6886C12N15/1072C12Q1/6809C12Q1/6827C12Q1/6869C12Q1/6881C12Q1/6883C12Q2600/106C12Q2600/118C12Q2600/156C12Q2600/158C12Q2600/16Y02A90/10

Abstract

Claims (33)

1 . A method comprising:

(a) amplifying recombined nucleic acids comprising complementary determining region 3 (CDR3) sequences from T cell receptor (TCR) genes or immunoglobulin genes from at least one sample of nucleic acids from T cells and/or B cells obtained from an individual having an autoimmune disease, wherein the at least one sample is a blood sample;

(b) spatially isolating individual molecules of the amplified recombined nucleic acids;

(c) generating one or more clonotype profiles by sequencing the spatially isolated amplified recombined nucleic acids, wherein each of the one or more clonotype profiles comprises at least 10,000 sequence reads of at least 30 base pairs per read;

(d) determining one or more correlating clonotypes of the autoimmune disease in the individual using the one or more clonotype profiles;

(e) identifying the individual as having a level of the one or more correlating clonotypes indicative of an active episode of the autoimmune disease; and

(f) administering an autoimmune disease therapy to the individual to treat the autoimmune disease.

2 . The method according to claim 1 , wherein the at least one sample comprises nucleic acids from at least 10,000 T-cells.

3 . The method according to claim 2 , wherein the correlating clonotypes comprise TCRβ CDR3 sequences.

4 . The method according to claim 1 , wherein the at least one sample comprises nucleic acids from at least 10,000 B-cells.

5 . The method according to claim 1 , wherein the sequencing comprises sequencing by synthesis using reversibly terminated labeled nucleotides.

6 . The method according to claim 1 , wherein generating the one or more clonotype profiles comprises coalescing sequence reads into different clonotypes of the recombined nucleic acids of the sample whenever the sequence reads are distinct with a confidence of at least 99.9 percent based on an error rate.

7 . The method according to claim 1 , wherein the recombined nucleic acids comprise genomic DNA.

8 . The method according to claim 1 , wherein the recombined nucleic acids comprise cDNA.

9 . The method according to claim 1 , wherein the autoimmune disease is systemic lupus erythematosus (SLE), multiple sclerosis (MS), rheumatoid arthritis (RA), or ankylosing spondylitis.

10 . The method according to claim 9 , wherein the autoimmune disease therapy comprises an anti-inflammatory therapy.

11 . The method according to claim 1 , wherein the autoimmune disease is rheumatoid arthritis (RA) and the autoimmune disease therapy comprises a disease-modifying antirheumatic drug (DMARD).

12 . A method comprising:

(a) amplifying recombined nucleic acids comprising complementary determining region 3 (CDR3) sequences from T cell receptor (TCR) genes or immunoglobulin genes from at least one sample of nucleic acids from T cells and/or B cells obtained from an individual suspected of having an autoimmune disease, wherein the at least one sample is a blood sample;

(b) spatially isolating individual molecules of the amplified recombined nucleic acids;

(c) generating one or more clonotype profiles by sequencing the spatially isolated amplified recombined nucleic acids, wherein each of the one or more clonotype profiles comprises at least 10,000 sequence reads of at least 30 base pairs per read;

(d) determining presence of one or more correlating clonotypes of the autoimmune disease in the individual using the one or more clonotype profiles;

(e) identifying the individual as having the autoimmune disease based on the presence of the one or more correlating clonotypes of the autoimmune disease; and

(f) administering an autoimmune disease therapy to the individual to treat the autoimmune disease.

13 . The method according to claim 12 , wherein the at least one sample comprises nucleic acids from at least 10,000 T-cells.

14 . The method according to claim 13 , wherein the correlating clonotypes comprise TCRβ CDR3 sequences.

15 . The method according to claim 12 , wherein the sequencing comprises sequencing by synthesis using reversibly terminated labeled nucleotides.

16 . The method according to claim 12 , wherein generating the one or more clonotype profiles comprises coalescing sequence reads into different clonotypes of the recombined nucleic acids of the sample whenever the sequence reads are distinct with a confidence of at least 99.9 percent based on an error rate.

17 . The method according to claim 12 , wherein the recombined nucleic acids comprise genomic DNA.

18 . The method according to claim 12 , wherein the recombined nucleic acids comprise cDNA.

19 . The method according to claim 12 , wherein the autoimmune disease is systemic lupus erythematosus (SLE), multiple sclerosis (MS), rheumatoid arthritis (RA), or ankylosing spondylitis.

20 . The method according to claim 19 , wherein the autoimmune disease therapy comprises an anti-inflammatory therapy or an antibody therapy.

21 . The method according to claim 12 , wherein the autoimmune disease is rheumatoid arthritis (RA) and the autoimmune disease therapy comprises a disease-modifying antirheumatic drug (DMARD).

Assignments (2)

Continuity (8)

References Cited (400)